As­traZeneca spells out a ma­jor drop in the risk of death for stage 3 NSCLC pa­tients tak­ing Imfinzi — and why that's im­por­tant

As­traZeneca’s top team un­der Pas­cal So­ri­ot $AZN has spent the past 5 years prov­ing that it could do se­ri­ous block­buster de­vel­op­ment work. And few tri­als have been as im­por­tant to forg­ing that rep as PA­CIF­IC, which of­fered clear ev­i­dence that its PD-L1 check­point Imfinzi al­lowed pa­tients with un­re­sectable stage 3 non-small cell lung can­cer to live longer.

This morn­ing, As­traZeneca ex­ecs turned up at the World Con­fer­ence on Lung Can­cer in Toron­to to spell out the promis­ing over­all sur­vival da­ta the phar­ma gi­ant had claimed with a top-line re­port last spring. The study was pub­lished in the New Eng­land Jour­nal of Med­i­cine.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Life Sciences Senior Associate

General Catalyst

San Francisco, CA, USA